Correction: miR-1323 promotes cell migration in lung adenocarcinoma by targeting Cbl-b and is an early prognostic biomarker - Takeaways - MDSpire

Correction: miR-1323 promotes cell migration in lung adenocarcinoma by targeting Cbl-b and is an early prognostic biomarker

  • By

  • Huan Zhao

  • Chunlei Zheng

  • Yizhe Wang

  • Kezuo Hou

  • Xianghong Yang

  • Yang Cheng

  • Xiaofang Che

  • Shilin Xie

  • Shuo Wang

  • Tieqiong Zhang

  • Jian Kang

  • Yunpeng Liu

  • Dianzhu Pan

  • Xiujuan Qu

  • Xuejun Hu

  • Yibo Fan

  • July 3, 2026

  • 0 min

Share

  • 1

    The article discusses the role of miR-1323 in enhancing cell migration in lung adenocarcinoma through Cbl-b targeting.

  • 2

    References for two studies were retracted and replaced with new citations regarding microRNA in lung cancer.

  • 3

    A mistake was identified in Figure 4B, where an image of miR-1323 mimics in A549 cells was repeated.

  • 4

    An error was also found in Figure 6D, where an image of Cbl-b siRNA in A549 cells was repeated.

  • 5

    The original article has been updated to correct these errors and provide accurate references.

Original Source(s)

Correction: miR-1323 promotes cell migration in lung adenocarcinoma by targeting Cbl-b and is an early prognostic biomarker

  • by Huan Zhao, Chunlei Zheng, Yizhe Wang, Kezuo Hou, Xianghong Yang, Yang Cheng, Xiaofang Che, Shilin Xie, Shuo Wang, Tieqiong Zhang, Jian Kang, Yunpeng Liu, Dianzhu Pan, Xiujuan Qu, Xuejun Hu, Yibo Fan

  • July 3, 2026

Related Content

An IHC-derived TLS–CD8–macrophage immune niche score predicts major pathological response to neoadjuvant chemoimmunotherapy in resectable NSCLC

Short-term quantitative CT changes in synchronous ground-glass nodules during immune checkpoint inhibitor therapy in patients with lung cancer

ASCO26: Julia Rotow, MD, Silevertinib in Lung Cancer

Dana-Farber Cancer Institute's Dr. Julia Rotow reported on a study looking at silevertinib, with data showing it may offer a new first-line option for hard-to-treat EGFR non-small cell lung cancer variants, with encouraging brain activity and manageable side effects.

  • July 1, 2026

  • 1 min